Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre L Triozzi

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Anticancer Research|March 25, 2010
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanomaPierre L Triozzi, Wayne Aldrich
Cancers|November 13, 2013
The role of the immune response in merkel cell carcinomaPierre L Triozzi, Anthony P Fernandez
Future Oncology (London, England)|February 17, 2012
Blood biomarkers for uveal melanomaPierre L Triozzi, Arun D Singh
The British Journal of Ophthalmology|December 18, 2010
Blood biomarkers of uveal melanoma metastasisPierre L Triozzi, Arun D Singh
Ocular Oncology and Pathology|May 14, 2016
Adjuvant Therapy of Uveal Melanoma: Current StatusPierre L Triozzi, Arun D Singh
Expert Opinion on Biological Therapy|October 4, 2011
VB-111 for cancerPierre L Triozzi, Ernest C Borden
Investigative Ophthalmology & Visual Science|April 27, 2011
Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanomaPierre L Triozzi, Wayne Aldrich, Arun Singh
Journal of Hematotherapy & Stem Cell Research|July 15, 2003
Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinomaPierre L Triozzi, Julian Kim, Wayne Aldrich
Frontiers in Oncology|August 22, 2013
Circulating melanoma cells: scoping the targetPowrnima Joshi, Maciej Zborowski, Pierre L Triozzi
Vaccine|October 13, 2010
Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonistsPierre L Triozzi, Wayne Aldrich, Selvarangan Ponnazhagan
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Anticancer Research|March 25, 2010
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanomaPierre L Triozzi, Wayne Aldrich
Cancers|November 13, 2013
The role of the immune response in merkel cell carcinomaPierre L Triozzi, Anthony P Fernandez
Future Oncology (London, England)|February 17, 2012
Blood biomarkers for uveal melanomaPierre L Triozzi, Arun D Singh
The British Journal of Ophthalmology|December 18, 2010
Blood biomarkers of uveal melanoma metastasisPierre L Triozzi, Arun D Singh
Ocular Oncology and Pathology|May 14, 2016
Adjuvant Therapy of Uveal Melanoma: Current StatusPierre L Triozzi, Arun D Singh
Expert Opinion on Biological Therapy|October 4, 2011
VB-111 for cancerPierre L Triozzi, Ernest C Borden
Investigative Ophthalmology & Visual Science|April 27, 2011
Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanomaPierre L Triozzi, Wayne Aldrich, Arun Singh
Journal of Hematotherapy & Stem Cell Research|July 15, 2003
Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinomaPierre L Triozzi, Julian Kim, Wayne Aldrich
Frontiers in Oncology|August 22, 2013
Circulating melanoma cells: scoping the targetPowrnima Joshi, Maciej Zborowski, Pierre L Triozzi
Vaccine|October 13, 2010
Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonistsPierre L Triozzi, Wayne Aldrich, Selvarangan Ponnazhagan
Pageof 6